Investor Overview


About Natera

Natera is a rapidly-growing diagnostics company with proprietary bioinformatics and molecular technology for analyzing DNA. Natera’s complex technology has been proven clinically and commercially in the prenatal testing space and the Company is actively researching its applications in the liquid biopsy space for developing products with oncology applications.

Since 2009, Natera has launched seven molecular diagnostic tests, many of which are available through major health plans accounting for more than 140 million covered lives in the United States. The Company’s own robust laboratory processes thousands of genetic tests per month.

Natera’s goal is to transform the way people – both providers and patients – respond to and manage genetic diseases.

Learn More About Natera

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.


Recent News

Natera to Present New Data at ASN Kidney Week 2020 Showing Clinical Differentiation of the Prospera™ Test  -  10/21/2020
Represents largest dd-cfDNA retransplant study to date and demonstrates clinical value of proprietary background cfDNA technology SAN CARLOS, Calif. , Oct. 21, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present More »
Natera Teams Up with the George Lopez Foundation on the #GLFTrickShot Kidney Disease Awareness Challenge  -  10/5/2020
Celebrities and the public are making creative golf trick shot videos to create awareness and encourage donations for kidney disease patients SAN CARLOS , Calif. and LOS ANGELES , Oct. 5, 2020 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced More »
Court Rejects ArcherDX's Motion to Dismiss Natera's Patent Infringement Case  -  10/5/2020
Upholds validity of Natera's patents; patent case against ArcherDX continues SAN CARLOS, Calif. , Oct. 5, 2020 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today reports that the U.S. District Court of Delaware has rejected all of ArcherDX's More »
Natera Announces Prospective Randomized Clinical Trial to Evaluate Palbociclib in Early Stage Breast Cancer Patients Who Test Positive with Signatera™  -  10/2/2020
SAN CARLOS, Calif. , Oct. 2, 2020 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA, today announced that its  Signatera molecular residual disease (MRD) test will be used in the DARE study, a multi-center clinical trial of palbociclib (IBRANCE®), a CDK4/6 More »
Medicare Issues Draft Local Coverage Determination for Signatera™ in Immunotherapy Response Monitoring  -  9/24/2020
Proposes expanded coverage of the Signatera minimal residual disease (MRD) test in a broad range of solid tumor types and indications including immunotherapy (IO) monitoring SAN CARLOS, Calif. , Sept. 24, 2020 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a pioneer and global leader in cell-free More »

Upcoming Events

More events are coming soon.

Past events


Footer disclaimer

Footer disclaimer

© Natera 2020. All Rights Reserved. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.